Adverum Makes Job Cuts To Advance Wet AMD Gene Therapy

Moving On After Last Year's Safety Issues

The California-based biotech is reducing its workforce to help finance a Phase II study of Ixo-vec, its eye gene therapy which has been blighted by safety concerns.

Old Eye
• Source: Archive

Adverum Biotechnologies, Inc. is the latest gene therapy player to feel the financial pinch but the US firm hopes a major restructuring will safeguard funds to advance its one-time wet age-related macular degeneration (AMD) treatment.

The California-based biotech has unveiled restructuring measures which CEO Laurent Fischer said were “intended to enable us to fully support...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies